This company listing is no longer active
CINC Stock Overview
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CinCor Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.06 |
| 52 Week High | US$43.15 |
| 52 Week Low | US$10.53 |
| Beta | 0 |
| 1 Month Change | 0.94% |
| 3 Month Change | 9.54% |
| 1 Year Change | 2.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 81.63% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About CinCor Pharma's (NASDAQ:CINC) Cash Burn Situation
Nov 06
CinCor Pharma prices upsized stock and pre-funded warrants offering
Aug 11CinCor Pharma says last patient randomized in phase 2 trial for baxdrostat to treat hypertension
Jul 26We Think CinCor Pharma (NASDAQ:CINC) Can Afford To Drive Business Growth
Jul 23We're Hopeful That CinCor Pharma (NASDAQ:CINC) Will Use Its Cash Wisely
Apr 08CinCor: 2022 Data Catalysts Will Derisk The Stock
Apr 07Shareholder Returns
| CINC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.9% | -1.9% | -2.8% |
| 1Y | 2.0% | 2.7% | 24.1% |
Return vs Industry: CINC underperformed the US Pharmaceuticals industry which returned 3.4% over the past year.
Return vs Market: CINC exceeded the US Market which returned -11.5% over the past year.
Price Volatility
| CINC volatility | |
|---|---|
| CINC Average Weekly Movement | 44.4% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CINC's share price has been volatile over the past 3 months.
Volatility Over Time: CINC's weekly volatility has increased from 26% to 44% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 19 | Marc M. de Garidel | www.cincor.com |
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.
CinCor Pharma, Inc. Fundamentals Summary
| CINC fundamental statistics | |
|---|---|
| Market cap | US$1.27b |
| Earnings (TTM) | -US$88.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-14.4x
P/E RatioIs CINC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CINC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$88.09m |
| Earnings | -US$88.09m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.01 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CINC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/25 10:45 |
| End of Day Share Price | 2023/02/23 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CinCor Pharma, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael DiFiore | Evercore ISI |
| Madhu Kumar | Goldman Sachs |
| Yuchen Ding | Jefferies LLC |